Please use this identifier to cite or link to this item:
Title: Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review
Authors: Notarte, Kin Israel
Ver, Abbygail Therese
Velasco, Jacqueline Veronica
Pastrana, Adriel
Catahay, Jesus Alfonso
Salvagno, Gian Luca
Yap, Eric Peng Huat
Martinez-Sobrido, Luis
Torrelles, Jordi B.
Lippi, Giuseppe
Henry, Brandon Michael
Keywords: Science::Medicine
Issue Date: 2022
Source: Notarte, K. I., Ver, A. T., Velasco, J. V., Pastrana, A., Catahay, J. A., Salvagno, G. L., Yap, E. P. H., Martinez-Sobrido, L., Torrelles, J. B., Lippi, G. & Henry, B. M. (2022). Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Critical Reviews in Clinical Laboratory Sciences, 59(6), 373-390.
Journal: Critical Reviews in Clinical Laboratory Sciences
Abstract: With the advent of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic, several vaccines have been developed to mitigate its spread and prevent adverse consequences of the Coronavirus Disease 2019 (COVID-19). The mRNA technology is an unprecedented vaccine, usually given in two doses to prevent SARS-CoV-2 infections. Despite effectiveness and safety, inter-individual immune response heterogeneity has been observed in recipients of mRNA-based vaccines. As a novel disease, the specific immune response mechanism responsible for warding off COVID-19 remains unclear at this point. However, significant evidence suggests that humoral response plays a crucial role in affording immunoprotection and preventing debilitating sequelae from COVID-19. As such, this paper focused on the possible effects of age, sex, serostatus, and comorbidities on humoral response (i.e. total antibodies, IgG, and/or IgA) of different populations post-mRNA-based Pfizer-BioNTech vaccination. A systematic search of literature was performed through PubMed, Cochrane CENTRAL, Google Scholar, Science Direct, medRxiv, and Research Square. Studies were included if they reported humoral response to COVID-19 mRNA vaccines. A total of 32 studies were identified and reviewed, and the percent differences of means of reported antibody levels were calculated for comparison. Findings revealed that older individuals, male sex, seronegativity, and those with more comorbidities mounted less humoral immune response. Given these findings, several recommendations were proposed regarding the current vaccination practices. These include giving additional doses of vaccination for immunocompromised and elderly populations. Another recommendation is conducting clinical trials in giving a combined scheme of mRNA vaccines, protein vaccines, and vector-based vaccines.
ISSN: 1040-8363
DOI: 10.1080/10408363.2022.2038539
Rights: © 2022 Informa UK Limited, trading as Taylor & Francis Group. All rights reserved.
Fulltext Permission: none
Fulltext Availability: No Fulltext
Appears in Collections:LKCMedicine Journal Articles

Citations 20

Updated on Dec 3, 2022

Web of ScienceTM
Citations 20

Updated on Dec 1, 2022

Page view(s)

Updated on Dec 3, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.